InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,035.69
(
-1.57%
)
US TECH 100
16,918.40
(
-2.26%
)
Dow Jones
37,815.92
(
-1.49%
)
Brent Oil
85.90
(
-1.59%
)
Bitcoin
60,345.87
(
-5.47%
)
Post# of 29271
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119515
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 29225

Wednesday, 04/17/2024 12:33:48 PM

Wednesday, April 17, 2024 12:33:48 PM

Post# of 29271
ABT 1Q24 Results by Business Segment 
  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency) 
 Medical devices*  45%       +14% 
 Diagnostics       22%       -16%† 
 Nutrition         21%        +8% 
 Pharmaceuticals‡  12%       +14%
61% of overall corporate sales were ex-US.

*Includes diabetes care.
‡Branded generics and biosimilars in emerging markets.

†Excluding COVID diagnostics, 1Q24 diagnostics sales were +5% YoY. 1Q24 COVID-diagnostics sales were $204M (9% of total 1Q24 diagnostic sales) vs $730M in 1Q23.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up